EricLawrenceEisenhauerMD
Obstetrics & Gynecology • Boston, MAGynecologic Oncology
Chief, Division of Gynecologic Oncology, Massachusetts General Hospital
Dr. Eisenhauer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
55 Fruit St
Boston, MA 02114Phone+1 617-724-4800Fax+1 617-724-6009- Is this information wrong?
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Gynecologic Oncology, 2004 - 2008
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Obstetrics and Gynecology, 2000 - 2004
University of California San Diego School of MedicineClass of 2000
Certifications & Licensure
MA State Medical License 2018 - 2025
OH State Medical License 2008 - 2019
NY State Medical License 2004 - 2010- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
- Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Dec 13
- Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12
- Join now to see all
Publications & Presentations
PubMed
- Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair.Wang, Y., Gao, B., Zhang, L., Wang, X., Zhu, X., Yang, H., Zhang, F., Zhu, X., Zhou, B., Yao, S., Nagayama, A., Lee, S., Ouyang, J., Koh, S., Eisenhauer, E., Zarrella,...> ;Nature Communications. 2024 Feb 21
- Minimally invasive interval cytoreductive surgery for advanced ovarian cancer.Melamed, A., Eisenhauer, E.> ;Journal of Surgical Oncology. 2024 Jan 1
- Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States.Jason N Silberman, Alexandra S Bercow, Allison A Gockley, Eric L Eisenhauer, Rachel Sisodia, Thomas Randall, Marcela G Del Carmen, Annekathryn Goodman, Cesar M Castro,...> ;Gynecologic Oncology. 2023 Aug 1
- Join now to see all
Press Mentions
Lymphadenectomy in Advanced Ovarian Cancer: Will It Improve Survival?March 19th, 2019
Lymphadenectomy Often Useless in Ovarian CancerMarch 1st, 2019
Dr. Eric L. Eisenhauer Has Been Recognized Among the Top in His Industry by the Expert Network©January 21st, 2016
Professional Memberships
- Society of Gynecologic OncologyMember
Hospital Affiliations
Massachusetts General HospitalBoston, Massachusetts
Newton-Wellesley HospitalNewton Lower Falls, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
